Bicarbonate

Bicarbonate

SCHEMBL578685

NC1CCC1.O=C(O)O

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL11593113 0.97 PEPD (0.41)
Bicarbonate SCHEMBL7136582 0.93 GABRR1 (0.42)
Bicarbonate SCHEMBL7136153 0.93 GABRR1 (0.42)
Bicarbonate SCHEMBL1702507 0.93
Cyclopentanamine SCHEMBL578697 0.90 THRB (0.39)
Carbamic Acid SCHEMBL578618 0.90
Bicarbonate SCHEMBL8743136 0.89
Cyclohexylamine SCHEMBL974340 0.87 CES2 (0.43)
Cyclooctanamine SCHEMBL11193013 0.87 CES2 (0.43)
Cycloheptanamine SCHEMBL720218 0.87 CES2 (0.43)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3169403-B9 ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES PROTAGONIST THERAPEUTICS INC (US) 2024-07-03 EP claimed
EP-3169403-B1 ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES PROTAGONIST THERAPEUTICS INC (US) 2024-02-14 EP claimed
EP-3209682-B1 CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS MERCK SHARP & DOHME (US) 2020-12-30 EP claimed
EP-2836485-B1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2018-01-10 EP claimed
EP-1765408-B1 POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY NOVO NORDISK AS (DK) 2015-12-09 EP claimed
EP-2289560-B1 POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY NOVO NORDISK AS (DK) 2015-04-22 EP claimed
EP-1006122-B1 PHENETHYLAMINE DERIVATIVES CHUGAI PHARMACEUTICAL CO LTD (JP) 2008-12-03 EP claimed
EP-0606881-B1 Cyclic pentapeptides having a beta-turn and a gamma-turn TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1999-05-12 EP claimed
EP-2027107-B1 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2012-02-15 EP disclosed
EP-2357181-A1 2,4-Diaminopyrimidines as inhibitors of cell cycle kinases Boehringer Ingelheim International GmbH (DE) 2011-08-17 EP disclosed
EP-2027107-A1 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2009-02-25 EP disclosed
WO-2007132010-A1 2, 4 -DIAMINO PYRIMIDINES AS CELL CYCLE KINASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-11-22 WO disclosed
EP-0991626-A2 PYRIMIDIN-2,4,6-TRION DERIVATIVES, METHOD FOR PRODUCING THE SAME AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS Roche Diagnostics GmbH (DE) 2000-04-12 EP disclosed
EP-0640618-B1 Tetrahydronaphthalene-peptide derivatives HOFFMANN LA ROCHE (CH) 1999-10-20 EP disclosed
WO-1998058915-A2 PYRIMIDIN-2,4,6-TRION DERIVATIVES AND THEIR USE AS METALLOPROTEASE-INHIBITORS ROCHE DIAGNOSTICS GMBH (DE) 1998-12-30 WO disclosed
EP-0729972-A1 Peptide derivatives of tetrahydronaphthalene F. HOFFMANN-LA ROCHE AG (CH) 1996-09-04 EP disclosed
EP-0640618-A1 Tetrahydronaphthalene-peptide derivatives F. HOFFMANN-LA ROCHE AG (CH) 1995-03-01 EP disclosed
EP-0592791-A2 Tricyclic compounds and peptide derivatives thereof F. HOFFMANN-LA ROCHE AG (CH) 1994-04-20 EP disclosed